1. Moore EA, Wilkinson S. The promise of low dose naltrexone therapy, potential benefits in cancer, autoimmune, neurological and infectious disorders. McFarland; 2008. http://www.elainemoore.com/Books/NEWThePromiseofLDNTherapy/tabid/102/Default.aspx . Last visited 27 Feb 2016.
2. Food and Drug Association. Revia label and approval history. FDA Website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo . Last visited 27 Feb 2016.
3. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003687/WC500185583.pdf . Last visited 4 Jun 2016.
4. Therapeutic Goods Administration. https://search.tga.gov.au/s/search.html?collection=tga-websites-web&query=naltrexone . Last visited 4 Jun 2016.
5. Schecter AJ, Friedman JG, Grossman DJ. Clinical use of naltrexone (EN-1639A): part I: safety and efficacy in pilot studies. Am J Drug Alcohol Abuse. 1974;1(2):253–69.